Advisory Board December 16, 2024

The United Kingdom indefinitely banned the use of puberty blockers to treat minors with gender dysphoria, with the government’s Commission on Human Medicines saying that the use of these drugs poses an “unacceptable safety risk.”

UK bans puberty blockers for minors

Earlier this year, an independent study commissioned by England’s National Health Service (NHS) concluded that gender medicine was operating on “shaky foundations” when it came to evidence for certain medical treatments, including prescriptions for hormones to pause puberty or to change physical characteristics.

Following the study, puberty blockers for treating gender dysphoria in minors were temporarily banned. Although the ruling was challenged, Britain’s High Court upheld the temporary ban in July, saying that it was lawful.

In early December,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Health System / Hospital, Provider, Survey / Study, Trends
How 3 hospitals are reimagining behavioral crisis care
How Health Systems Can Collaborate on AI Tools
Critical access hospitals face uphill battle: 6 things to know
AdventHealth's plans for new Florida hospital move forward
Trends 2025: The demand for interim revenue cycle executives

Share This Article